JAK2 and essential thrombocythemia: In this study, there is no significant statistical difference regarding the percentage of those mutant genes in ET patients with JAK2 V617F positive mutation versus the JAK2 V617F negative group, and also there is no significant statistical difference regarding the percentage of those mutant genes in patients with CVS risk factors versus the patients with non-CVS risk factors.